- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Cardiovascular Psychiatry and Neurology
Volume 2012 (2012), Article ID 204043, 8 pages
Are Cardiovascular Risk Factors Associated with Verbal Learning and Memory Impairment in Patients with Schizophrenia? A Cross-Sectional Study
1EA 3279—Public Health, Chronic Disease, and Quality of Life Research Unit, Aix-Marseille University, 13005 Marseille, France
2Department of Psychiatry, Sainte-Marguerite University Hospital, 13009 Marseille, France
3Department of Addiction, Sainte-Marguerite University Hospital, 13009 Marseille, France
4Department of Psychiatry, La Conception University Hospital, 13009 Marseille, France
Received 11 July 2012; Revised 25 September 2012; Accepted 20 October 2012
Academic Editor: Kenji Hashimoto
Copyright © 2012 Christophe Lancon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- B. E. Kopald, K. M. Mirra, M. F. Egan, D. R. Weinberger, and T. E. Goldberg, “Magnitude of impact of executive functioning and IQ on episodic memory in Schizophrenia,” Biological Psychiatry, vol. 71, pp. 545–551, 2012.
- K. H. Nuechterlein, D. M. Barch, J. M. Gold, T. E. Goldberg, M. F. Green, and R. K. Heaton, “Identification of separable cognitive factors in schizophrenia,” Schizophrenia Research, vol. 72, no. 1, pp. 29–39, 2004.
- H. A. Nasrallah, “Linkage of cognitive impairments with metabolic disorders in schizophrenia,” American Journal of Psychiatry, vol. 167, no. 10, pp. 1155–1157, 2010.
- K. Yaffe, A. Kanaya, K. Lindquist et al., “The metabolic syndrome, inflammation, and risk of cognitive decline,” The Journal of the American Medical Association, vol. 292, no. 18, pp. 2237–2242, 2004.
- M. G. Dik, C. Jonker, H. C. Comijs et al., “Contribution of metabolic syndrome components to cognition in older individuals,” Diabetes Care, vol. 30, no. 10, pp. 2655–2660, 2007.
- C. Y. Liu, H. D. Zhou, Z. Q. Xu, W. W. Zhang, X. Y. Li, and J. Zhao, “Metabolic syndrome and cognitive impairment amongst elderly people in Chinese population: a cross-sectional study,” European Journal of Neurology, vol. 16, no. 9, pp. 1022–1027, 2009.
- E. van den Berg, R. P. Kloppenborg, R. P. C. Kessels, L. J. Kappelle, and G. J. Biessels, “Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition,” Biochimica et Biophysica Acta, vol. 1792, no. 5, pp. 470–481, 2009.
- A. J. Mitchell, D. Vancampfort, K. Sweers, R. van Winkel, W. Yu, and M. De Hert, “Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis,” Schizophrenia Bulletin. In press.
- P. Pramyothin and L. Khaodhiar, “Metabolic syndrome with the atypical antipsychotics,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 17, no. 5, pp. 460–466, 2010.
- B. F. Grant, D. S. Hasin, S. P. Chou, F. S. Stinson, and D. A. Dawson, “Nicotine dependence and psychiatric disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions,” Archives of General Psychiatry, vol. 61, no. 11, pp. 1107–1115, 2004.
- J. Koskinen, J. Löhönen, H. Koponen, M. Isohanni, and J. Miettunen, “Prevalence of alcohol use disorders in schizophrenia—a systematic review and meta-analysis,” Acta Psychiatrica Scandinavica, vol. 120, no. 2, pp. 85–96, 2009.
- J. M. Meyer, H. A. Nasrallah, J. P. McEvoy et al., “The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome,” Schizophrenia Research, vol. 80, no. 1, pp. 9–18, 2005.
- J. I. Friedman, S. Wallenstein, E. Moshier et al., “The effects of hypertension and body mass index on cognition in schizophrenia,” American Journal of Psychiatry, vol. 167, no. 10, pp. 1232–1239, 2010.
- APA: DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC, USA, 4th edition, 2000.
- S. R. Kay, L. A. Opler, and A. Fiszbein, “Significance of positive and negative syndromes in chronic schizophrenia,” British Journal of Psychiatry, vol. 149, pp. 439–448, 1986.
- T. F. Heatherton, L. T. Kozlowski, R. C. Frecker, and K. O. Fagerstrom, “The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire,” British Journal of Addiction, vol. 86, no. 9, pp. 1119–1127, 1991.
- D. C. Delis, J. H. Kramer, E. Kaplan, and B. A. Ober, California Verbal Learning Test: Research Edition-Adult Version, The Psychological Corporation, New York, NY, USA, 1987.
- S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement,” Circulation, vol. 112, no. 17, pp. 2735–2752, 2005.
- A. Cheng, J. B. Braunstein, C. Dennison, C. Nass, and R. S. Blumenthal, “Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy,” Clinical Cardiology, vol. 25, no. 5, pp. 205–212, 2002.
- G. A. Bray, “Obesity is a chronic, relapsing neurochemical disease,” International Journal of Obesity, vol. 28, no. 1, pp. 34–38, 2004.
- K. F. Holden, K. Lindquist, F. A. Tylavsky, C. Rosano, T. B. Harris, and K. Yaffe, “Serum leptin level and cognition in the elderly: findings from the Health ABC Study,” Neurobiology of Aging, vol. 30, no. 9, pp. 1483–1489, 2009.
- X. L. Li, S. Aou, Y. Oomura, N. Hori, K. Fukunaga, and T. Hori, “Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents,” Neuroscience, vol. 113, no. 3, pp. 607–615, 2002.
- Y. Oomura, N. Hori, T. Shiraishi et al., “Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats,” Peptides, vol. 27, no. 11, pp. 2738–2749, 2006.
- C. Reitz, M. X. Tang, J. Manly, R. Mayeux, and J. A. Luchsinger, “Hypertension and the risk of mild cognitive impairment,” Archives of Neurology, vol. 64, no. 12, pp. 1734–1740, 2007.
- V. Manning, S. Betteridge, S. Wanigaratne, D. Best, J. Strang, and M. Gossop, “Cognitive impairment in dual diagnosis inpatients with schizophrenia and alcohol use disorder,” Schizophrenia Research, vol. 114, no. 1–3, pp. 98–104, 2009.
- C. R. Bowie, M. R. Serper, S. Riggio, and P. D. Harvey, “Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients,” Schizophrenia Bulletin, vol. 31, no. 1, pp. 175–182, 2005.
- A. Olincy, J. G. Harris, L. L. Johnson et al., “Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia,” Archives of General Psychiatry, vol. 63, no. 6, pp. 630–638, 2006.
- M. S. D'Souza and A. Markou, “Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits,” Neuropharmacology, vol. 62, pp. 1564–1573, 2012.
- R. A. Whitmer, S. Sidney, J. Selby, S. C. Johnston, and K. Yaffe, “Midlife cardiovascular risk factors and risk of dementia in late life,” Neurology, vol. 64, no. 2, pp. 277–281, 2005.
- M. J. Smith, L. Wang, W. Cronenwett et al., “Alcohol use disorders contribute to hippocampal and subcortical shape differences in schizophrenia,” Schizophrenia Research, vol. 131, pp. 174–183, 2011.
- R. E. Drake, S. M. Essock, A. Shaner et al., “Implementing dual diagnosis services for clients with severe mental illness,” Psychiatric Services, vol. 52, no. 4, pp. 469–476, 2001.
- S. M. Essock, R. E. Drake, and B. J. Burns, “A research network to evaluate assertive community treatment: introduction,” The American Journal of Orthopsychiatry, vol. 68, no. 2, pp. 176–178, 1998.
- M. R. Picciotto and M. Zoli, “Nicotinic receptors in aging and dementia,” Journal of Neurobiology, vol. 53, no. 4, pp. 641–655, 2002.
- R. Jurado-Barba, I. Morales-Muñoz, B. A. del Manzano et al., “Relationship between measures of inhibitory processes in patients with schizophrenia: role of substance abuse disorders,” Psychiatry Research, vol. 190, pp. 187–192, 2011.
- E. L. M. Ochoa and J. Lasalde-Dominicci, “Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking,” Cellular and Molecular Neurobiology, vol. 27, no. 5, pp. 609–639, 2007.
- H. Adachi, H. Yanai, and Y. Hirowatari, “The underlying mechanisms for olanzapine-induced hypertriglyceridemia,” Journal of Clinical Medicine Research, vol. 4, pp. 206–208, 2012.
- C. Garcia-Rizo, E. Fernandez-Egea, C. Oliveira, A. Justicia, M. Bernardo, and B. Kirkpatrick, “Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features,” Psychiatry Research, vol. 198, no. 2, pp. 212–215, 2012.
- H. A. Nasrallah and J. W. Newcomer, “Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care,” Journal of Clinical Psychopharmacology, vol. 24, no. 5, supplement 1, pp. S7–S14, 2004.
- H. Y. Meltzer and S. R. McGurk, “The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia,” Schizophrenia Bulletin, vol. 25, no. 2, pp. 233–255, 1999.